Ticker

The Company's Annual General and Special Meeting will be held on Thursday, July 30, 2026, at 11:00 a.m. (Vancouver time), at 15th Floor, 1111 West Hastings Street, Vancouver, British Columbia, with virtual attendance available via Microsoft Teams Dr. Frederick D.

Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholders The Canadian Securities Exchange has accepted the share issuance, allowing the Company to complete the settlement Company remains well-positioned with C$4.96 million in cash and short-term investments as of its most recent quarter ended February 28, 2026…

VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates for diseases with significant unmet medical needs, under a disciplined, pharmaceutical development platform, progressing assets from early development to clinical stages, through focused subsidiary companies, today…

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced that its Chief Executive…

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced its unaudited interim financial results for the…